Security Snapshot

BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) Institutional Ownership

CUSIP: 07725L102

13F Institutional Holders and Ownership History from Q1 2016 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

237

Shares (Excl. Options)

30.58MFull value: 30,581,071 · shares · 30 Sep 2026

Price

$365.94

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+2,584,650
Value change
+$950,665,952
Number of holders
237
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
1,501,807,694
SEC-reported price per share
$384.50
Insider filing price
$384.50
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share is tracked under CUSIP 07725L102.
  • 237 institutions reported positions in Q3 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 282 to 237 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $9.93BFull value: $9,929,244,904 · USD · 30 Jun 2026
    to
    $11.19BFull value: $11,192,747,822 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 237 institutions filings for Q3 2026.

Open SEC evidence

Security key

07725L102

13F reference period

Q3 2026

13F holders

237

13D/G owners

3

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
ONC
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 7.8% -2.5% $43,405,871,459 115,912,814 0% Julian C. Baker 14 Sep 2026
HHLR ADVISORS, LTD. 4.9% -26% $16,788,174,431 -$5,939,951,540 68,551,141 -26% HHLR Advisors, Ltd. 09 May 2025
OYLER JOHN 3.6% $19,784,574,277 54,065,077 OYLER JOHN 30 Sep 2026
As of 30 Sep 2026, 237 institutional investors reported holding
30.58MFull value: 30,581,071 · shares · 30 Sep 2026
shares of BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC). This represents 2% of the company’s total
1.5BFull value: 1,501,807,694 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
43
Headline period
Q3 2026
Rows shown
1-25 of 43
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 30,581,071 $11,192,747,822 +$950,665,952 $365.94 237
2026 Q2 34,833,536 $9,929,244,904 -$7,626,107 $284.97 282
2026 Q1 34,810,508 $10,331,637,555 +$276,646,958 $296.97 282
2025 Q4 33,825,761 $10,275,450,364 +$214,065,011 $303.81 284
2025 Q3 32,958,063 $11,226,015,297 -$346,958,018 $340.70 261
2025 Q2 34,445,503 $8,338,029,358 -$2,097,913,474 $242.07 240
2025 Q1 42,522,929 $11,571,304,178 -$300,776,021 $272.17 260
2024 Q4 43,668,178 $8,065,581,343 -$576,365,574 $184.71 222
2024 Q3 46,519,526 $10,440,141,817 -$116,771,313 $224.51 221
2024 Q2 46,804,066 $6,679,478,929 +$49,458,709 $142.67 195
2024 Q1 46,433,670 $7,261,664,670 +$228,390,098 $156.39 198
2023 Q4 44,965,141 $8,109,589,388 -$358,939,167 $180.36 201
2023 Q3 46,934,356 $8,443,617,070 -$8,576,628 $179.87 195
2023 Q2 47,044,110 $8,388,424,595 -$134,114,517 $178.30 200
2023 Q1 47,729,619 $10,288,729,347 -$365,549,782 $215.53 214
2022 Q4 49,411,792 $10,871,665,562 -$822,129,900 $219.94 206
2022 Q3 53,491,519 $7,213,600,064 -$18,667,417 $134.82 204
2022 Q2 53,542,991 $8,666,746,485 -$222,094,321 $161.85 217
2022 Q1 54,923,857 $10,369,831,154 -$143,839,726 $188.60 228
2021 Q4 55,475,829 $15,026,076,469 -$242,691,110 $270.93 247
2021 Q3 56,111,399 $20,367,209,544 +$187,897,220 $363.00 242
2021 Q2 55,478,557 $19,043,602,189 -$143,508,273 $343.19 259
2021 Q1 55,905,428 $19,451,416,879 +$655,221,281 $348.08 241
2020 Q4 54,296,531 $14,026,755,839 -$183,663,940 $258.39 234
2020 Q3 54,822,916 $15,700,067,419 +$1,338,448,467 $286.44 238
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .